Epidermolysis Bullosa Studies & Clinical Trials | Dermatology | Stanford Medicine

Skip to Content Skip to Local Navigation Skip to Global Navigation

Stanford Medicine Dermatology

Health Care
- Locations
- Stanford Health Care
- Stanford Children's Health
- Emergency Department
- Dial 911 in the event of a medical emergency
Explore Health Care

Learn how we are healing patients through science & compassion

Back
Research
Research News

Newly identified process of gene regulation challenges accepted science

Explore Research

Learn how we are fueling innovation

Back
Education
Education News

Among first-year medical students, wide variety of experiences

Explore Education

Learn how we empower tomorrow's leaders

Back
Give
Support Stanford Medicine
Support Children's Health
Back
About
Stanford School of Medicine

Stanford Health Care

Stanford Children's Health

Back
Site Search

Search by name or topic...

Faculty
Faculty
- Clinical Faculty
- Open Faculty Positions
Education
Education
Grand Rounds
Grand Rounds
Research
Research
- EB Update
- Clinical Trials
Resources
Resources
Patient Care
Patient Care
- Subspecialties
Contact

Epidermolysis Bullosa Studies & Clinical Trials

Alfred T. Lane, MD., on EB Research

Gene Transfer Study for RDEB
Characteristics of Dystrophic Epidermolysis Bullosa
Epidermolysis Bullosa Clinical Research Consortium (EBCRC) Study
NK-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa (EB) Patients
A Phase 3 Study of SD-101 Cream in Patients with Epidermolysis Bullosa
Autologous Fibroblast Study for RDEB

©2017 Stanford Medicine

Terms of Use
See us on Facebook
See us on Twitter

Stanford University
Stanford School of Medicine
Stanford Health Care
Stanford Children's Health
Lucile Packard Children's Hospital Stanford
University Healthcare Alliance